In­cyte stops PhI­II tri­al for PI3K in­hibitor af­ter pri­ma­ry end­point fail­ure

In­cyte has called it quits on a Phase III study for its oral PI3K in­hibitor, parsaclis­ib, a year af­ter with­draw­ing its ac­cel­er­at­ed ap­proval pitch for a dif­fer­ent in­di­ca­tion.

The study was look­ing at parsaclis­ib plus rux­oli­tinib ver­sus a place­bo plus rux­oli­tinib in myelofi­bro­sis (MF) pa­tients 18 years and old­er who had an “in­ad­e­quate” re­sponse to rux­oli­tinib monother­a­py. MF is a rare, chron­ic blood can­cer that af­fects the bone mar­row and the pro­duc­tion of blood cells.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.